Phathom Pharmaceuticals, Inc. PHAT Business Segments — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s business segments — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s business segments — revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) reported business segments — revenue of $58.3M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s business segments — revenue changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s business segments — revenue increased by 104.4% year-over-year, from $28.52M to $58.3M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s business segments — revenue?
- Over 2 years (2023 to 2025), Phathom Pharmaceuticals, Inc.'s business segments — revenue has grown at a 1502.4% compound annual growth rate (CAGR), from $682K to $175.11M.
- What does business segments — revenue mean?
- This represents the total gross income generated from the sale of pharmaceutical products within the company's primary operating segment. It serves as a key indicator of market adoption and commercial success for the firm's therapeutic portfolio. Growth in this metric reflects the effective scaling of product distribution and patient access.